The veracity of these two claims - the first comprehensive review in 30 years - matters because it reflects a disconnect between ambition and reality. How can you effectively engage in a process without understanding the past and its place in history?
Why it matters that this review is neither comprehensive nor the first in 30 years
October 9, 2023 Latest NewsBioPharmaComment
Latest Video
New Stories
-
Reform was justified because a committee prioritising clinical considerations was 'culturally' problematic
January 4, 2026 - - Latest News -
AdAlta and SHcell launch cancer collaboration to progress breakthrough CAR-T therapy
January 2, 2026 - - Australian Biotech -
Cabinet documents from the year that led to transformational changes
January 1, 2026 - - Latest News -
US pricing push gets real with Australia included in comparison list
December 22, 2025 - - Latest News -
Parsimony has unfortunately become an enduring test of the institution's legitimacy
December 20, 2025 - - Latest News -
PBAC delivers a broad range of outcomes in November, including for obesity
December 20, 2025 - - Latest News -
Takeda’s next-generation psoriasis therapy delivers landmark Phase 3 results
December 19, 2025 - - Latest News

